35.40 0.00 (0.00%)
After hours: 4:19PM EDT
|Bid||32.50 x 100|
|Ask||37.85 x 1000|
|Day's Range||35.33 - 36.05|
|52 Week Range||26.95 - 52.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.50|
NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is drawing a considerable amount of attention in the biotechnology space as we start a fresh week of trading, with the activity rooted in an event that hit press shortly before markets closed out for the session last Friday. Here is what happened. For anybody not familiar with Pacira, this one […] The post Here’s Why The Latest News Is A Big Deal For Pacira Pharmaceuticals appeared first on Market Exclusive.
Pacira Pharmaceuticals (PCRX) was a big mover last session, as the company saw its shares rise more than 12% on Friday amid huge volumes.
EXPAREL is now an opioid-free option for use as an interscalene brachial plexus block for upper extremity surgeries. Conference call on Monday, April 9, 2018 at 8:30 a.m. EST. PARSIPPANY, N.J., April 06, ...
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
Heron catapulted to a three-year high Monday after its post-surgical pain drug outperformed a rival from Pacira.
Short interest is moderate for PCRX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 31.
Stock Monitor: Pacira Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 9, 2018 / Active-Investors.com has just released a free earnings report on Lannett Co., Inc. (NYSE: LCI ). If you want ...
PARSIPPANY, N.J., March 06, 2018-- Pacira Pharmaceuticals, Inc. today announced that the company is scheduled to participate in an analyst-led fireside chat at the 2018 Barclays Global Healthcare Conference ...
Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.
On a per-share basis, the Parsippany, New Jersey-based company said it had profit of 11 cents. Earnings, adjusted for stock option expense and amortization costs, came to 38 cents per share. The results ...
--EXPAREL ® net product sales expected to be in the range of $300 to $310 million in 2018--. --Conference call today at 8:30 a.m. ET--. PARSIPPANY, N.J., Feb. 28, 2018-- Pacira Pharmaceuticals, Inc. today ...
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018, at 8:30 ...
PARSIPPANY, N.J. and KNOXVILLE, Tenn., Feb. 27, 2018--. To improve patient outcomes and combat a segment of the national opioid epidemic, The University of Tennessee Medical Center and Pacira Pharmaceuticals, ...
PARSIPPANY, N.J., Feb. 22, 2018-- Pacira Pharmaceuticals, Inc. today announced that it will report its fourth quarter and year ended December 31, 2017 financial results before the open of the U.S. markets ...
Apricus Biosciences, Inc. (NASDAQ:APRI) is an early mover in the biotechnology space this week, with the company putting out an update on a regulatory development from its lead development asset. Unfortunately, for both the company and its shareholders, the update lands squarely on the negative end of the spectrum. So what happened? Apricus just reported […] The post Here’s What’s Moving Apricus Biosciences And Pacira Pharmaceuticals appeared first on Market Exclusive.